Review



normalized rna-seq data of pdcls  (Brunton Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Brunton Inc normalized rna-seq data of pdcls
    ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary <t>PDCLs</t> were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based <t>on</t> <t>RNA-Seq</t> in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.
    Normalized Rna Seq Data Of Pdcls, supplied by Brunton Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normalized+rna-seq+data+of+pdcls/normalized+rna+seq+data+of+pdcls/pmc09220834-251-4-12
    Average 90 stars, based on 1 article reviews
    normalized rna-seq data of pdcls - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype"

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

    Journal: JCI Insight

    doi: 10.1172/jci.insight.151353

    ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary PDCLs were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based on RNA-Seq in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.
    Figure Legend Snippet: ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary PDCLs were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based on RNA-Seq in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.

    Techniques Used: Glo Assay, Microscopy, Expressing, Western Blot, Control, MANN-WHITNEY, RNA Sequencing

    Related Articles

    Glo Assay:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    Microscopy:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    Expressing:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    Western Blot:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    Control:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    MANN-WHITNEY:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    RNA Sequencing:

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).



    Similar Products

    normalized rna-seq data of pdcls  (Brunton Inc)
    90
    Brunton Inc normalized rna-seq data of pdcls
    ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary <t>PDCLs</t> were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based <t>on</t> <t>RNA-Seq</t> in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.
    Normalized Rna Seq Data Of Pdcls, supplied by Brunton Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normalized+rna-seq+data+of+pdcls/normalized+rna+seq+data+of+pdcls/pmc09220834-251-4-12
    Average 90 stars, based on 1 article reviews
    normalized rna-seq data of pdcls - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary PDCLs were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based on RNA-Seq in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.

    Journal: JCI Insight

    Article Title: Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

    doi: 10.1172/jci.insight.151353

    Figure Lengend Snippet: ( A ) Dose-response curves of 4 human PDOs after 6 days of treatment with JNJ-64619178. Viability was determined with CellTiter-Glo assay. Sensitive: red, resistant: blue. ( B ) Microscopy of a sensitive organoid treated with the indicated dose of JNJ-64619178 over 6 days. Scale bar: 500 μM. ( C ) GI 50 values of 24 human PDOs were calculated. Sensitive: red, resistant: blue. ( D ) MYC expression was analyzed in selected PDOs ( n = 7) by Western blot. β-Actin: loading control. Sensitive: red, resistant: blue. One Western blot was performed. ( E ) GI 50 values of 18 primary PDCLs were calculated. Sensitive: red, resistant: blue. ( F ) Relative MYC protein expression, determined by Western blot, in sensitive ( n = 3, red) and resistant ( n = 15, blue) PDCL was compared. P value of Mann-Whitney U test is depicted. MYC Western blot was performed once. ( G ) MYC mRNA expression based on RNA-Seq in JNJ-64619178–sensitive and –resistant PDCLs. * P < 0.05; Mann-Whitney U test. ( H ) JNJ-64619178 GI 50 values of PDOs were grouped into quartiles and differentially expressed genes of most sensitive (first quartile, n = 6) and most resistant (fourth quartile, n = 6) PDOs were calculated. The log-fold change was used as a rank to perform a preranked GSEA. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( I ) JNJ-64619178 GI 50 values of PDCL were grouped into quartiles and analyzed corresponding to H . Sensitive: first quartile, n = 3, resistant: fourth quartile, n = 3. Depicted are the top 10 HALLMARK signatures; q value is color coded. ( J ) Proteomics-based protein expression of PRMT5i-sensitive (first quartile, n = 6) and -resistant (fourth quartile, n = 6) PDOs was used to determine differentially expressed proteins. All proteins upregulated in sensitive PDOs were analyzed using the Enrichr web tool. Combined scores of the HALLMARK signatures with an adjusted P value and q < 0.05 are shown.

    Article Snippet: Normalized RNA-Seq data of PDCLs were obtained from the supplementary information of Brunton and colleagues ( ).

    Techniques: Glo Assay, Microscopy, Expressing, Western Blot, Control, MANN-WHITNEY, RNA Sequencing